Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with unresectable (cannot be surgically removed) stage III or IVA esophageal squamous cell carcinoma confirmed by biopsy or cell sample
- Good overall health and physical function (able to do light activities; ECOG score 0–1)
- Normal or acceptable blood counts, liver, kidney, and heart function within 2 weeks of starting the trial
- Measurable cancer that can be tracked on imaging scans
- Never had radiation to the chest or chemotherapy for esophageal cancer before
- No other active cancer diagnoses in the past 5 years, except certain treated skin or cervical cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This study compares two standard approaches for treating esophageal cancer before surgery: chemotherapy combined with radiation versus chemotherapy combined with immunotherapy. The goal is to see which approach works better for shrinking tumors and improving outcomes in patients whose cancer is considered removable.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial compares surgery versus a strong combination of chemotherapy and radiation for people with esophageal squamous cell carcinoma that has been treated first with immunotherapy. It aims to find which approach leads to better outcomes after the initial immunotherapy and chemotherapy.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.